{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:57:55Z","timestamp":1760608675171},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ejca.2011.10.036","type":"journal-article","created":{"date-parts":[[2011,11,29]],"date-time":"2011-11-29T16:44:04Z","timestamp":1322585044000},"page":"289-296","source":"Crossref","is-referenced-by-count":30,"title":["A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study"],"prefix":"10.1016","volume":"48","author":[{"given":"Birgit","family":"Geoerger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Estlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nad\u00e8ge","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Doz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Lardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo De","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Prados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.10.036_b0005","unstructured":"Rinehart KL, Lithgow-Berelloni AM. Novel Antiviral and Cytotoxic Agent. PCT Int. Pat. Appl. WO 91.04985, Apr. 18, 1991; GB Appl. 89\/22,026, Sept. 29, 1989. Chem Abstr. 1991,115."},{"key":"10.1016\/j.ejca.2011.10.036_b0010","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/bjc.1998.570","article-title":"In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells","volume":"78","author":"Depenbrock","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2011.10.036_b0015","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/sj.onc.1205972","article-title":"Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta","volume":"21","author":"Garcia-Fernandez","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2011.10.036_b0020","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/jpet.107.132662","article-title":"Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1\/c-Jun NH2-terminal kinase activation in human melanoma cells","volume":"324","author":"Mu\u00f1oz-Alonso","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2011.10.036_b0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1074\/jbc.M201010200","article-title":"Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK","volume":"278","author":"Cuadrado","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2011.10.036_b0030","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.cdd.4401898","article-title":"Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation","volume":"13","author":"Gonzalez-Santiago","year":"2006","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ejca.2011.10.036_b0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.leu.2402788","article-title":"Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4","volume":"17","author":"Broggini","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2011.10.036_b0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","article-title":"Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes","volume":"57","author":"Straight","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2011.10.036_b0045","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdi311","article-title":"VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia","volume":"16","author":"Biscardi","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2011.10.036_b0050","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/sj.leu.2402972","article-title":"In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development","volume":"17","author":"Bresters","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2011.10.036_b0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/pbc.21976","article-title":"Initial testing of aplidin by the pediatric pre-clinical testing program","volume":"53","author":"Morton","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2011.10.036_b0060","article-title":"Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24-hour, weekly schedule","volume":"19","author":"Anthoney","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.036_b0065","article-title":"Phase I clinical and pharmacokinetic study of the marine compound Aplidin (APL) administered as a 3 hour infusion every 2 weeks","volume":"21","author":"Ciruelos","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.036_b0070","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1078-0432.CCR-07-1652","article-title":"Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors","volume":"14","author":"Izquierdo","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.10.036_b0075","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1200\/JCO.2005.09.357","article-title":"Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies","volume":"23","author":"Faivre","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.036_b0080","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/annonc\/mdl165","article-title":"Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115","volume":"17","author":"Maroun","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2011.10.036_b0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/md7030451","article-title":"Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium","volume":"7","author":"Dumez","year":"2009","journal-title":"Mar Drugs"},{"key":"10.1016\/j.ejca.2011.10.036_b0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CMR.0b013e32832bbde6","article-title":"Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma","volume":"19","author":"Eisen","year":"2009","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2011.10.036_b0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/COC.0b013e31819fdf5e","article-title":"Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma","volume":"33","author":"Baudin","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.036_b0100","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-10-0469","article-title":"Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma","volume":"16","author":"Mateos","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.10.036_b0105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.lungcan.2007.10.019","article-title":"Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer","volume":"60","author":"Peschel","year":"2008","journal-title":"Lung cancer"},{"key":"10.1016\/j.ejca.2011.10.036_b0110","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.1998.16.3.966","article-title":"Conduct of phase I trials in children with cancer","volume":"16","author":"Smith","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.036_b0115","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","article-title":"Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology","volume":"17","author":"Gralla","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.036_b0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2011.10.036_b0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0731-7085(03)00557-0","article-title":"Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection","volume":"34","author":"Celli","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ejca.2011.10.036_b0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00001813-200404000-00003","article-title":"Progress in the clinical development of new marine-derived anticancer compounds","volume":"15","author":"Jimeno","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2011.10.036_b0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/md7010057","article-title":"Phase II randomized study of plitidepsin (aplidin), alone or in association with l-carnitine, in patients with unresectable advanced renal cell carcinoma","volume":"7","author":"Schoffski","year":"2009","journal-title":"Mar Drugs"},{"key":"10.1016\/j.ejca.2011.10.036_b0140","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1200\/JCO.2000.18.9.1900","article-title":"Phase I trials in pediatric oncology: perceptions of pediatricians from the United Kingdom Children\u2019s Cancer Study Group and the Pediatric Oncology Group","volume":"18","author":"Estlin","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911008719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911008719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T02:28:02Z","timestamp":1543372082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911008719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0959804911008719"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.10.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}